Mary Pan is new VP of Asia Pacific and Hiroshi Ichikawa leads ICON’s operations in Japan
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced two new leadership appointments to its Asia Pacific operations.
ICON provides a full range of clinical development services to support global and pan-Asian trials. ICON operates from 22 offices in Asia-Pacific and employs over 2,600 professionals in the region. ICON’s presence and capabilities in Japan, in particular in oncology, were strengthened in 2014 through the acquisition of Aptiv Solutions, which included Japanese CRO, Niphix.
Vice President, Asia Pacific
Mary Pan has been appointed Vice President, Asia Pacific, where she will lead ICON’s continued growth and expansion in the region. Hiroshi Ichikawa has been appointed Vice President and General Manager of ICON’s operations in Japan.
Mary brings to ICON over 15 years of global pharmaceutical and clinical development expertise with a strong track record in Asia. Mary joins ICON from Becton Dickinson, a leading medical technology company, where she was head of strategy and innovation in Asia. Prior to that Mary was Managing Director, Asia-Pacific, for ClinTec International. Mary has also held senior medical affairs and clinical development roles in Crucell (Johnson & Johnson) and Pfizer. Mary holds Bachelor degrees in Economics and Psychology and an MBA from Brown University and has a Law degree from the University of Edinburgh.
Hiroshi Ichikawa joins ICON with 30 years of CRO and pharmaceutical industry experience in Japan. Prior to ICON, Ichikawa-san was Executive Vice President and Senior Director of the Regulatory Science Department at A2Healthcare Corporation, an ITOCHU company. Ichikawa-san was also President and CEO of Asklep Inc. following its acquisition of PPCJ Corporation, a CRO he founded in 2008. Ichikawa-san also spent 16 years in leadership positions with CMIC Japan and was Project Leader for the Clinical Development Division of Sankyo. Ichikawa-san holds a Masters in Veterinary Medicine from Yamaguchi University.
Commenting on the appointments, Dr. Nuala Murphy, President, ICON Clinical Research Services, said: “Asia-Pacific continues to be an important region for our clients and we are committed to growing our presence and enhancing our capabilities in the region. I’m delighted to welcome Mary and Ichikawa-san to the leadership team in Asia. Their strong knowledge of the Asian clinical development landscape, coupled with their demonstrated leadership in growing successful operations in Asia, will be invaluable as we look to expand in this important region.”
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 81 locations in 37 countries and has approximately 11,300 employees.
Further information is available at ICON
ICON Media Contact
+44 (0) 207 067 0190
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website.